All Posts
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
13 Jan, 2022 | 08:17h | UTCThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin – Drugs
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
13 Jan, 2022 | 08:13h | UTC
Systematic Review: In patients who are about to undergo noncardiac surgery, biomarkers (BNP/NT‐proBNP, troponin or their combination) may provide added prognostic value to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all‐cause mortality. The results cannot be interpreted as conclusive due to the high risks of bias in most papers.
13 Jan, 2022 | 08:15h | UTC
Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.
13 Jan, 2022 | 08:12h | UTCTucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)
Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.
12 Jan, 2022 | 09:11h | UTC
Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.
12 Jan, 2022 | 09:14h | UTCSee also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
Cohort Study: In preterm premature rupture of membranes at 24-31 weeks, antibiotic prophylaxis based on third-generation cephalosporin may be associated with improved perinatal outcomes compared to amoxicillin.
13 Jan, 2022 | 08:10h | UTCAntibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks’ gestation: perinatal and 2-year outcomes in the EPIPAGE-2 cohort – BJOG (link to abstract – $ for full-text)
Recommendations on patient prioritization for outpatient Anti-SARS-CoV-2 therapies or preventive strategies when there are logistical or supply constraints.
12 Jan, 2022 | 09:06h | UTC
Commentary on Twitter
https://twitter.com/NIHCOVIDTxGuide/status/1475510894121697287
International study identifies predictors of severe outcomes in children with COVID-19.
12 Jan, 2022 | 09:05h | UTCNews Release: International study identifies predictors of severe outcomes in children with COVID-19 – University of Calgary
Original Study: Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments: The Global PERN–COVID-19 Study – JAMA Network Open
How do death rates from COVID-19 differ between people who are vaccinated and those who are not?
12 Jan, 2022 | 09:02h | UTC
Commentary from the author on Twitter
Updated: Now the ratio is 20.
The COVID death rate among unvaccinated people is 20-times higher than among vaccinated people.
This is the latest age-standardized data from Swizerland.
[From our post with @redouad on death rates by vaccination status: https://t.co/nNmfYAk0m1] pic.twitter.com/dRwkOWIRBa
— Max Roser (@MaxCRoser) December 26, 2021
Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.
12 Jan, 2022 | 09:09h | UTCCommentaries:
Pfizer antiviral pills may be risky with other medications – NBC News
See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
Podcast: Long COVID Pearls.
12 Jan, 2022 | 09:04h | UTC#315 Long COVID with Dr. Monica Verduzco-Gutierrez – The Curbsiders
[Preprint] Saliva swabs may be the preferred sample for Omicron detection.
12 Jan, 2022 | 08:58h | UTCSaliva swabs are the preferred sample for Omicron detection – medRxiv
Commentary: Study suggests saliva swabs may be more suitable for omicron detection – News Medical
Perspective | Covid-19: Is it safe to reduce the self-isolation period?
12 Jan, 2022 | 09:00h | UTCCovid-19: Is it safe to reduce the self-isolation period? – The BMJ
RCT: High-dose weekly Semaglutide (2.4 mg) resulted in increased weight loss compared to daily Liraglutide (3.0 mg).
12 Jan, 2022 | 08:55h | UTCEffect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
In this randomized clinical trial of 338 participants, mean body weight change from baseline to 68 weeks was –15.8% with semaglutide vs –6.4% with liraglutide, a statistically significant difference. https://t.co/8tktjqw4mE pic.twitter.com/BxrL1XPpKv
— JAMA (@JAMA_current) January 11, 2022
German Guideline: Oxygen therapy in the acute care of adult patients.
12 Jan, 2022 | 08:57h | UTCGerman S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients – Respiration
Two years of coronavirus: how pandemic unfolded around the world.
12 Jan, 2022 | 09:02h | UTCTwo years of coronavirus: how pandemic unfolded around the world – The Guardian
Discriminative accuracy of chronic obstructive pulmonary disease screening instruments in 3 low- and middle-income country settings.
12 Jan, 2022 | 08:54h | UTCDiscriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings – JAMA (free for a limited period)
Editorial: Screening for Chronic Obstructive Pulmonary Disease: Unmet Needs and Future Considerations
News release: Simple screening for common lung disease could relieve millions globally – University College London
Commentary from the author on Twitter (thread – click for more)
🔺Screening for #COPD in LMIC🔺
The results of our @COPDGECo study from @ucl are published today in @JAMA_current.
Discriminative Accuracy of COPD Screening Instruments in Low- and Middle-Income Countries
🇳🇵🇵🇪 🇺🇬 https://t.co/7aq8XXfI8E – part of @JAMANetwork— John Hurst (@ProfHurst) January 11, 2022
Clinical Review: Diagnostic reasoning in cardiovascular medicine.
12 Jan, 2022 | 08:49h | UTCDiagnostic reasoning in cardiovascular medicine – The BMJ
RCT: Endoscopic sinus surgery with medical therapy vs. medical therapy alone for chronic rhinosinusitis with nasal polyps.
12 Jan, 2022 | 08:51h | UTCEndoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW Research—Endoscopic sinus surgery + medical therapy > medical therapy alone in pts w/ chronic rhinosinusitis w/ nasal polyps (although minimal clinically important difference was not met)
From Wytske Fokkens & colleagues https://t.co/VKxCQZ97Am pic.twitter.com/IzXq712lNL
— The Lancet Respiratory Medicine (@LancetRespirMed) January 8, 2022
RCT: Among patients younger than 21 years of age with provoked thromboembolism, anticoagulation for 6 weeks was non-inferior vs. 12 weeks on the risk of recurrence and bleeding events.
12 Jan, 2022 | 08:53h | UTCEffect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients – JAMA (free for a limited period)
RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).
12 Jan, 2022 | 08:43h | UTCRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6
— NEJM (@NEJM) January 5, 2022
Clinical Update: Management and outcomes of extreme preterm birth.
12 Jan, 2022 | 08:48h | UTCManagement and outcomes of extreme preterm birth – The BMJ
RCT: Eltrombopag added to immunosuppression is associated with improved hematologic response vs. immunosuppression alone in previously untreated patients with severe aplastic anemia.
12 Jan, 2022 | 08:46h | UTCEltrombopag Added to Immunosuppression in Severe Aplastic Anemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A randomized trial comparing immunosuppression (horse ATG and cyclosporine) with the same therapy plus eltrombopag showed more rapid and complete responses with the addition of eltrombopag. https://t.co/nH7rkeCMAS pic.twitter.com/i8iTIq8FSG
— NEJM (@NEJM) January 5, 2022
A cluster randomized trial in a yaws-endemic area of Papua New Guinea showed a reduction in the community prevalence of yaws with three rounds of mass administration of azithromycin at 6-month intervals compared with one round of mass administration of azithromycin followed by two rounds of targeted treatment.
12 Jan, 2022 | 08:44h | UTCTrial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Data from a community-based trial in Papua New Guinea suggest that more than one round of mass drug administration should be considered as part of the strategy for yaws eradication. https://t.co/7Cfuz16CUa pic.twitter.com/pVRyefOlTb
— NEJM (@NEJM) January 6, 2022